Trial Profile
A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Sep 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CheckMate 714
- Sponsors Bristol-Myers Squibb
- 23 Sep 2023 This trial has been completed in Spain, Belgium, Netherlands, Sweden, Norway, and Italy, according to European Clinical Trials Database record.
- 24 Mar 2022 Status changed from active, no longer recruiting to completed.
- 07 Nov 2021 This trial has been completed in Czech Republic, according to European Clinical Trials Database record.